Literature DB >> 18345528

[Hormone therapy with estrogens and gestagens in peri- and post-menopause].

G Emons1.   

Abstract

Hormone therapy with estrogens (combined with progestin for women who have not been hysterectomized) is the most efficacious treatment for climacteric symptoms. A few years ago hormone therapy was considered to be an ideal prevention for cardio-vascular disease, osteoporosis, dementia and other diseases. Large prospective randomized trials have changed this paradigm. Hormone therapy should only be used with a clear indication (moderate to severe climacteric symptoms and - with limitations - prevention of osteoporosis). The lowest effective dose should be used for the shortest possible time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18345528     DOI: 10.1007/s00108-008-2107-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

Review 2.  Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review.

Authors:  Anne Nedrow; Jill Miller; Miranda Walker; Peggy Nygren; Laurie Hoyt Huffman; Heidi D Nelson
Journal:  Arch Intern Med       Date:  2006-07-24

Review 3.  Clinical practice. Management of menopausal symptoms.

Authors:  Deborah Grady
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

4.  Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004.

Authors:  Anthony S Robbins; Christina A Clarke
Journal:  J Clin Oncol       Date:  2007-06-25       Impact factor: 44.544

5.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

6.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Authors:  Marcia L Stefanick; Garnet L Anderson; Karen L Margolis; Susan L Hendrix; Rebecca J Rodabough; Electra D Paskett; Dorothy S Lane; F Allan Hubbell; Annlouise R Assaf; Gloria E Sarto; Robert S Schenken; Shagufta Yasmeen; Lawrence Lessin; Rowan T Chlebowski
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

Review 7.  Prevention of hormone-related cancers: breast cancer.

Authors:  Barbara K Dunn; D Lawrence Wickerham; Leslie G Ford
Journal:  J Clin Oncol       Date:  2005-01-10       Impact factor: 44.544

8.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

9.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Authors:  Andrew G Glass; James V Lacey; J Daniel Carreon; Robert N Hoover
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

10.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.